Acute Flare of Bullous Pemphigus with Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer

Rohan Garje, Justin J. Chau, Jina Chung, Karolyn Wanat, Yousef Zakharia

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

In the past decade, the resurgence of immunotherapy has changed the landscape of cancer therapy. Checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1 on lymphocytes, and programmed death ligand-1 on tumors cells are currently utilized in the management of several cancers. These agents are double-edged sword with the positive effect being robust antitumor response but on the other side they can throttle up the normal immunologic homeostasis in a negative way, leading to adverse autoimmune toxicities. These adverse toxicities are frequent if patients have active autoimmune disorders. Here, we report a rare case of quiescent bullous pemphigoid which flared after initiation of pembrolizumab, a programmed death ligand-1 inhibitor.

Original languageEnglish (US)
Pages (from-to)42-44
Number of pages3
JournalJournal of Immunotherapy
Volume41
Issue number1
DOIs
StatePublished - 2018
Externally publishedYes

Keywords

  • bullous pemphigus
  • corticosteroids
  • Immunotherapy
  • pembrolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Acute Flare of Bullous Pemphigus with Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer'. Together they form a unique fingerprint.

Cite this